Schizophrenia involves positive and negative symptom domains. Negative symptoms often remain despite available treatments and persist in a large number of patients. Furthermore, they are associated with considerable functional impairment and increased morbidity. No specifi c treatments are approved by the Food and Drug Administration (FDA) for management of negative symptoms. This article reviews the current state of research regarding the treatment of negative symptoms, including novel pharmacologic and neuromodulatory therapies.
ASJC Scopus subject areas
- Psychiatry and Mental health